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httpcense.Abstract Background: Community acquired pneumonia (CAP) is a widespread disease, brain
natriuretic peptide (BNP) shown to be elevated in patients with congestive heart failure, acute myo-
cardial infarction and massive pulmonary embolism, BNP levels have been found to be signiﬁcantly
elevated in CAP with a positive correlation to CRP and also low levels of BNP predict treatment
success.
Objective: The aim of this study was to evaluate the utility of cardiac stress marker B-type
natriuretic peptide in patients with CAP without sepsis or shock.
Patients and methods: 26 patients with CAP were eligible for study in addition to 10 healthy con-
trol cases, cardiac stress marker BNP and inﬂammation marker (CRP, white blood cell count, ESR)
were measured in patients with CAP.
Results: The mean serum level of initial BNP level was signiﬁcantly higher (86.75 ± 25.91 pg/
ml) in patients with CAP than the control group (30.70 ± 6.77 pg/ml) with p-value <0.001 and alsot Medicine Department, Fac-
reet, Mansoura 35116, Egypt.
.com (E.O. Arram).
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294 E.O. Arram et al.signiﬁcantly lower after treatment (40.15 ± 9.60) with p-value <0.001, BNP signiﬁcantly positively
correlated with (CRP) in patients before treatment (r= 0.709, p< 0.001) and also positively cor-
related with CRP after treatment (r= 0.490, p= 0.011), there was signiﬁcant negative correlation
between initial BNP level and partial arterial oxygen pressure (r= 0.409, p= 0.038). The optimal
cut-off for BNP was 47.0 pg/ml at admission vs 39.5 pg/ml after treatment.
Conclusion: In this study BNP levels show a transient rise in patients with community acquired
pneumonia and correlate well with CRP, low levels of BNP adequately identify patients with an
uncomplicated disease course.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Table 1 Demographic and BNP (initial) data of the case
control study population.
Cases (n= 26) Control (n= 10) P Value
Age (years) 48.54 ± 5.46 45.40 ± 4.90 0.122
Sex 0.763
Male 17 (65.4%) 6 (60%)
Female 9 (34.6%) 4 (40%)
BNP (pg/ml) 86.73 ± 25.91 30.70 ± 6.77 <0.001
Data are represented as mean ± SD.Introduction
Community-acquired pneumonia (CAP) is a common and lead-
ing infectious cause of death throughout the world. Although
the mortality rate in CAP patients has decreased with wide-
spread use of antibiotic therapy, the mortality rate for hospita-
lised CAP patients ranges between 10% and 15% [1,2].
Brain natriuretic peptide (BNP) is a neurohormone secreted
by the heart in response to myocardial stretch caused by vol-
ume overload. It has been demonstrated to be a neurohumoral
marker for left ventricular dysfunction and a potent prognostic
marker in congestive heart failure patients [3].
BNP regulates a wide array of physiological effects includ-
ing natriuresis, diuresis and vasodilatation, the main stimulus
for the secretion of BNP is cardiac stress reﬂected by myocar-
dial stretch and pressure or volume overload [4].
Recently pro-inﬂammatory cytokines and the activation of
the sympathetic nervous system have been identiﬁed as addi-
tional triggers inducing BNP secretion [5].
They have been studied for the diagnosis and prognosis of
patients with congestive heart failure, myocardial infarction,
pulmonary embolism and sepsis [6,7].
Consequently, BNP levels may reﬂect the severity of pneu-
monia, displayed by pulmonary hypertension, right ventricular
pressure overload and the inﬂammatory cytokine response, as
well as the presence of disease-relevant co-morbidities, namely
heart failure and renal dysfunction. In a pilot study we found
promising results for the ability of BNP to predict death in se-
lected patients with CAP [8].
In patients affected by an infectious disease but without
sepsis or shock, study results are still controversial [9,10].
It has been shown that increased BNP levels in patients
with acute phase pf Kawasaki disease signiﬁcantly decrease
after treatment [11].
The aim of this study was to evaluate the utility of BNP in
CAP without sepsis or shock.
Patients and methods
The case control study was conducted on 26 cases with the
diagnosis of community acquired pneumonia (CAP) and
healthy control cases, both patients and control were cross
matched for age and sex.
CAP was deﬁned by the presence of one or several of the
following recently acquired respiratory signs or symptoms,
cough, sputum production, dyspnoea, core body tempera-
ture > 38.0 C, auscultatory ﬁndings of abnormal breath
sounds and rales, white blood cell count >10 or
<4 · 109 cells L1 and an inﬁltrate on chest radiograph [12].Exclusion criteria
Exclusion criteria were history of heart failure, clinical, radio-
logical, or echocardiographic evidence of heart failure, history
of renal failure, chronic obstructive pulmonary disease,
cirrhosis of liver, hypertensive heart disease, pregnancy, pul-
monary hypertension, pulmonary embolism, cystic ﬁbrosis,
active pulmonary tuberculosis, hospital-acquired pneumonia,
immunodepression.
All patients underwent laboratory tests at admission and at
15th day of the treatment which include white blood cell count,
erythrocyte sedimentation rate, C-reactive protein, arterial
blood gas (ABG), and BNP level.
CRP was analysed with a Ray Bio-Human CRP ELISA
(Enzyme-linked immunosorbent Assay) KIT (Ray Biotech,
Inc, USA), BNP assay was performed by the use of micro-
plate-based immunoassay (Abbot laboratories, Abott park,
IL).
Statistical analysis
Data were analysed using SPSS (Statistical Package for Social
Sciences) version 15. Qualitative data are presented as number
and percent. Comparison between groups was done by Chi-
Square test. Data were presented as mean ± SD. Paired t-test
was used for comparison within groups. Student t-test was
used to compare between two groups. Pearson’s correlation
coefﬁcient was used to test correlation between variables.
P< 0.05 was considered to be statistically signiﬁcant.
Results
This study was conducted on 26 cases with the diagnosis of
community acquired pneumonia (CAP) and 10 healthy control
cases, both patients and control were cross matched for age
and sex.
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Figure 1 Initial BNP level in cases and control group.
Table 2 Comparison between initial and after treatment levels of BNP, CRP, ESR and leucocytic count in patient group .
Before treatment After treatment P Value
BNP (pg/ml) 86.73 ± 25.91 41.15 ± 9.60 <0.001
CRP (mg/l) 127.19 ± 57.84 40.38 ± 11.95 <0.001
ESR (mm/h) 59.31 ± 12.70 28.77 ± 8.86 <0.001
Leucocytic count (106/ml) 16.53 ± 3.55 9.97 ± 1.99 <0.001
Signiﬁcant when P< 0.05.
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Figure 2 Correlation between initial BNP and initial CRP levels in patient group.
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study population as regards age and sex, initial BNP level mea-
surement in the cases and control.
The mean age among CAP patients was 48.54 ± 5.46 while
in the control group was 45.40 ± 4.90. The mean serum levelof initial B-type natriuretic peptide (BNP) was signiﬁcantly
higher (86.73 ± 25.91 pg/ml) in patients group than the con-
trol group 30.70 ± 6.77 (P< 0.001) (Fig. 1).
Statistically signiﬁcant decrease was observed between ini-
tial and after treatment levels of BNP (86.73 ± 25.91 pg/ml
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Figure 3 Correlation between BNP and CRP levels after treatment (at 15th day) in patient group.
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Figure 4 Correlation between initial BNP and PaO2 levels in patient group.
296 E.O. Arram et al.vs. 41.15 ± 9.60 pg/ml, P< 0.001), CRP (127.19 ± 57.84 mg/
l vs 40.38 ± 11.95 mg/l, P< 0.001), ESR (59.31 ± 12.70 mm/
h vs 28.77 ± 8.86 mm/h, P< 0.001) and leucocytic count
(16.53 ± 3.55 · 106/ml vs 9.97 ± 1.99 · 106/ml, P< 0.001)
as shown in Table 2.Figs. 2 and 3 show signiﬁcant positive correlation between
BNP and CRP before and after treatment (r= 0.709,
P< 0.001 and r= 0.490, P= 0.011 respectively).
Fig. 4 shows signiﬁcant negative correlation between initial
BNP and PaO2 (r= 0.409, P= 0.038).
Table 3 Prediction of pneumonia and treatment success in all patients with community acquired pneumonia. Area under the curve
(AUC) of receiver operating curve (ROC) characteristic plot analysis, BNP threshold to predict pneumonia and treatment success,
Sensitivity and speciﬁcity at both cut-off levels.
AUC SD 95% CI P Value Cut oﬀ BNP Sensitivity Speciﬁcity
BNP at admission 0.98 0.014 0.962–1.015 0.001 47.0 pg mL 96 100
BNP after treatment 0.82 0.068 0.690–0.956 0.003 39.5 pg mL 65 100
SD, standard deviation; CI, conﬁdence interval; BNP, B-type natriuretic peptide.
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Figure 5 Sensitivity and speciﬁcity stratiﬁed by calculated optimal BNP cut-off in patients with CAP at admission.
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treatment success in cases with CAP without sepsis or shock,
a receiver operating characteristic (ROC) analysis was per-
formed, The area under the curve in cases with CAP at admis-
sion (AUC 0.98; SD 0.014; 95% CI 0.962–1.015), optimal BNP
cut-off was 47.0 pg/ml, sensitivity and speciﬁcity were 96%,
100% respectively. The area under the curve in cases with
CAP after treatment (AUC 0.82; SD 0.068; 95% CI 0.690–
0.956), optimal BNP cut-off was 39.5 pg/ml, sensitivity and
speciﬁcity were 65%, 100% respectively as shown in Table 3,
Figs. 5 and 6.
Discussion
Community acquired pneumonia (CAP) is the leading infec-
tious cause of death in developed countries and remains the
sixth most common overall cause of death [13,14].
Community-acquired pneumonia is prevalent worldwide.
Community-acquired pneumonia in adults is commonly
caused by viruses, bacteria, Mycoplasma pneumoniae and Chy-lamidia pneumoniae. Antibiotic treatment for CAP is usually
empirical because the causative pathogen is rarely identiﬁed.
The majority of bacterial infections are caused by Streptococ-
cus pneumoniae, Haemophilus inﬂuenzae and Mycoplasma
pneumoniae and beta lactams, macrolids and ﬂourocinolons
are used frequently for treatment of CAP [15,16].
B-type natriuretic peptide (BNP) was ﬁrst isolated from the
porcine brain and subsequently from the heart of porcine and
rats [17]. BNP is a 32 amino acid peptide and plays a role in
vascular tonus and natriuresis. The mammalian heart synthes-
ises and secretes BNP, which has potent diuretic, natriuretic
and vascular smooth muscle-relaxing effects as well as complex
interactions with the hormonal and nervous systems [18].
Recently, BNP has been investigated as a predictive bio-
marker in CAP, in addition, several serum biomarkers such
as white blood cell (WBC) counts, C-reactive protein (CRP),
d-dimer and procalcitonin have also been investigated as po-
tential predictors of mortality of CAP [19–23].
Several studies demonstrated how BNP levels rise signiﬁ-
cantly in patients affected by sepsis [24,25].
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Figure 6 Sensitivity and speciﬁcity stratiﬁed by calculated optimal BNP cut-off in patients with CAP after admission.
298 E.O. Arram et al.But in patients affected by an infectious disease, without
sepsis or shock study results are still controversial, indeed, if
some authors found elevated BNP levels in microbial infec-
tions without sepsis, others did not ﬁnd any difference between
patients having early sepsis and control [9,10].
This study showed that mean BNP values are signiﬁcantly
increased transiently in CAP patients compared to control
healthy cases, similar results have been found by Yetkin
et al. [26]. C-reactive protein (CRP) is an acute-phase protein,
which is synthesized by the liver in response to infection or tis-
sue inﬂammation. A range of cytokines, including interleukin-
6, interleukin-1b and tumour necrosis factor, stimulate its pro-
duction [27]. CRP was ﬁrst identiﬁed in 1930 from the obser-
vation of patients with pneumonia. Its name was derived
from the fact that it reacted with the pneumococcal C-polysac-
charide in patients’ plasma during the acute phase of pneumo-
coccal pneumonia. Subsequently, it has been recognized as a
marker of inﬂammation, a so-called ‘acute-phase protein’.
An acute-phase protein has been described as a protein whose
plasma concentration increases or decreases by at least 25%
during an inﬂammatory process [28].
Circulating levels of proinﬂammatory cytokines, interleu-
kin-6 (IL-6), interleukin-1 beta (IL-1b) and tumour necrosis
factor alpha (TNF-a) are usually elevated in pneumonia
[29,30].
According to this knowledge proinﬂammatory cytokines
might increase plasma BNP from ventricles and CRP from
liver in pneumonia. It has been reported that BNP levels
might be affected by increased pulmonary artery pressure
and proinﬂammatory cytokines released from lung tissue
[8,31].Recent studies have shown signiﬁcant correlation between
CRP and BNP in patients with chronic renal failure and heart
failure [32,33].
Investigations comparing CRP level to white blood cell
count in patients with CAP, CRP levels were consistently
found to superiorly diagnose pneumonia [34]. Another recent
paper [35] conﬁrmed a signiﬁcant association between progno-
sis and CRP and WBC. In this study, CRP and white blood
cell count levels are high before treatment and signiﬁcantly de-
crease on 15th day of the treatment, also CRP levels signiﬁ-
cantly correlated with BNP before and after treatment.
As a signiﬁcant correlation has been shown between BNP
and IL-1b in patients with myocardial dysfunction, it can be
speculated that IL-1b released from the alveolar macrophages
might play a role in secretion of CRP and BNP. It is reason-
able to expect that the correlation between CRP and BNP ex-
ists in patients with pneumonia [26].
Burn et al. [36] concluded that C-reactive protein measure-
ments are useful in the ﬁrst week in follow up antibiotic treat-
ment for severe community acquired pneumonia similar results
were seen in our study.
The secretion of BNP has also been suggested to be trig-
gered by hypoxia, leading to pulmonary vasoconstriction, pul-
monary hypertension and right heart overload [37,38].
Patients with CAP usually suffer from partial hypoxia in
the pulmonary vascular system, in our study, BNP levels neg-
atively correlate with partial oxygen pressure.
Previous studies demonstrated that BNP level negatively
correlated with hypoxaemia in patients with COPD [39].
Moine et al. [40] reported that decreased level of partial
oxygen pressure correlated with severity of pneumonia while
Evaluation of B-type natriuretic peptide in patients with community acquired pneumonia 299Mueller et al. [8] detected higher levels in sever pneumonia,
and the highest levels of BNP were obtained in subjects who
died of pneumonia.
Also initial high level of BNP that decreased after antibiotic
treatment may be explained by proinﬂammatory cytokines
[26].
In this study, patients with CAP without sepsis or shock
and after exclusion of any diseases can affect BNP level, the
cut-off level to predict improvement was 39.5 pg mL, sensitiv-
ity and speciﬁcity were 65%, 100% respectively.
While Christ et al. [10] concluded that, BNP cut-off level to
predict improvement in 302 CAP patients with sepsis or shock
was 95.5 pg mL while sensitivity and speciﬁcity were 47.8%,
85.8% respectively, this difference may be attributed to small
number of this study.
In conclusion, BNP levels show a transient rise in patients
with community acquired pneumonia, and correlates well with
CRP, so we can use BNP as an acute phase reactant in pneu-
monia, and can be used as predictor of treatment success, the
limitation of this study is the small number of patients caused
by limited availability of appropriate subjects free of major dis-
eases which can be accused as a cause of increase in the level of
BNP.
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